Welcome to Teladoc second quarter 2020 earnings conference call and webcast. At this time, all participants are in place on listen only mode, and the floor will be open for your questions following management's prepared remarks. If you'd like to ask a question at that time, please press star one on your touch-tone phone. If at any point your question has been answered, you may remove yourself from the queue by pressing pound key. We ask that you please pick up your headset for optimal sound quality. Lastly, if you should require operator assistance, please press star zero. It's now my pleasure to turn the floor over to Patrick Feeley, Vice President of Investor Relations. You may begin.
Thank you, good afternoon. Today, after the market closed, we issued a press release announcing our second quarter 2020 financial results. This press release is available in the investor relations section of the teladochealth.com website. On this call to discuss the results are Jason Gorevic, our Chief Executive Officer, and Mala Murthy, our Chief Financial Officer. During this call, we will also provide our third quarter 2020 outlook, and our prepared remarks will be followed by a question and answer session. Please note that we will be discussing certain non-GAAP financial measures that we believe are important in evaluating Teladoc Health's performance. Details on the relationship between these non-GAAP measures to the most comparable GAAP measures and reconciliations thereof can be found in the press release that is posted on our website. Also, please note that forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995.
Such forward-looking statements are subject to factors that could cause the actual results for Teladoc Health to differ materially from those expressed or implied on this call. For additional information, please refer to our cautionary statement in our press release and our filings with the SEC, all of which are available on our website. I would now like to turn the call over to Jason.
Thank you, everyone, for joining us this afternoon. We reported the results of our second quarter by outperformance across all key financial and operational metrics driven by broad-based strength across the entire business. Particularly strong was our revenue in the quarter, which grew 85% over the prior year to $241 million. As a result of the increased demand for our services from clients and consumers, as well as including the results of InTouch Health for the second half of the year, we are significantly raising forward guidance, including full year revenue guidance of $980 million-$995 million. This represents an increase of $170 million-$180 million over our prior range, including an organic increase of over $100 million.
There's no doubt that the ongoing pandemic shines a spotlight on the integral role that virtual care plays within the healthcare system. When asked about virtual care, Secretary Alex Azar said, "I think we'd have a revolution if anyone tried to go backwards on telemedicine. This is now an embedded part of our healthcare system." I don't think I could have said it any better. The pandemic has accelerated the widespread adoption of virtual care, I'm confident there's no going back. To that end, while it's earlier than usual for us to be looking ahead to the upcoming year, due to the significant amount of change experienced this year, we thought it would be helpful to provide you with a preliminary view on how we're thinking about 2021.
The tremendous momentum and demand we're seeing across the business for our comprehensive product offering, including an impressive pipeline of new opportunities, gives us confidence in providing a preliminary outlook of 30% - 40% revenue growth for 2021. As the market leader, we've seen a significant acceleration in demand for our services. In the first half of the year, we onboarded nearly 15 million new paid members in the U.S., including 8.5 million new members during the second quarter, all of which have come on board under the traditional PMPM plus visit fee model. The marketplace has taken notice of our performance during the COVID outbreak. Our execution during the crisis, including the outstanding reliability of our platform and our ability to rapidly onboard physician capacity, has enhanced our reputation and further distanced Teladoc Health from the competition.
As a result, we are seeing increased inquiries for new potential client takeaways. For example, we recently signed a contract to provide our entire suite of clinical services to a Fortune 50 media company with well over 100,000 employees. This was a competitive takeaway that came to us due to our broad and comprehensive product portfolio and is scheduled to launch this fall. Turning to visit volumes, we provided approximately 2.8 million visits in the second quarter, representing growth of over 200% compared to the second quarter of 2019, and a 35% increase sequentially over the first quarter, despite the second quarter historically being a seasonally slower quarter. During this period of significant growth, we are extremely proud to see our patient satisfaction metrics climb as consumers benefit from the convenience, lower cost, and high-quality service.
It's important to drill down into the drivers of the accelerating visit growth. While we're certainly seeing long-term sustainable tailwinds are evident through a deeper look at the dynamic within the quarter. As discussed on last quarter's conference call, we experienced a sharp acceleration of visit volume during March and into the month of April as comprehensive national shelter in place orders began. Zero-dollar copays were implemented and brick and mortar facilities closed. Over the course of April and May, volume growth began to ease as the COVID curve flattened across the country, and overall infectious disease rates. Utilization stabilized at a level roughly 40% higher than prior to COVID in late May and throughout most of June. We began to see volumes re-accelerate as COVID continues to flare up across various geographies.
At the book of business level, we're currently experiencing visit volumes in the U.S. typically expect to see during the months. When we look at the individual state level, however, trends. On one hand, in several southern states where reopening was more rapid and COVID case volumes have accelerated, we are likewise experiencing a significant spike in demand and are now seeing visit volumes in these states exceed the initial peak levels of March and April. Conversely, over the past several weeks, in those states where reopening has been slower and COVID cases have remained well below the initial outbreak peak, we've seen visit volumes stabilize at levels well in excess of pre-COVID levels. In fact, we're seeing visit volumes grow in these states at more than 2x the rate of growth that we experienced just prior to COVID.
It's worth noting that physician office locations on COVID capacity levels after being down 70%, a sustained strength and visit volumes meaningfully higher sustained levels of going forward. Continuing on the theme of sustained levels of higher utilization, our unmatched engagement capabilities have enabled us to fully capitalize on the current macro consumer tailwinds, fueling the acceleration of new registration growth, which was up 150% year-over-year in the second quarter. Individuals represented over half of our visit volumes in the quarter, momentum going forward as we benefit from the flywheel dynamic that we discussed at our Investor Day earlier this year. I am particularly pleased to see the strength in adoption and utilization continue to be broad-based, as our diverse portfolio of services is enabling us to meet the varied needs of our members.
While general medical visits continue to exhibit significant growth, demand for specialist care, including dermatology and mental health, continue to grow even faster. We're seeing tremendous demand for mental health visits in particular, as visit volumes have grown sequentially in every month of the year, both on the B2B and DTC sides of the business. BetterHelp, our direct-to-consumer accelerating traction outperform our expectations. Turning now to our hospital and health systems channel. The second quarter saw us continue to experience tremendous growth and demand as provider clients are adopting our technology as a secure, effective, and efficient way to offer virtual visits at scale. The prolonged global crisis is highlighting the need for robust virtual care capabilities, and according to a recent survey conducted by McKinsey, about 60% of U.S. providers now view telehealth more favorably.
In that same analysis, McKinsey estimated that over $250 billion worth of U.S. healthcare spend could ultimately be virtualized, delivering material efficiencies to the system. Since the outbreak of the pandemic, we have seen a more than tenfold increase in utilization across our provider platform as our clients shift more of their encounters to virtual. Of particular note, we have seen a tremendous increase in scheduled pre-admission and post-discharge follow-up visits as the number of clinical use cases continues to expand. As a result of investments we've made in our highly configurable and customizable offerings, we are uniquely equipped with plans looking to enable their own physician groups on our platform. Including white-labeled solutions to both enable the practices to see their own patients virtually and addition network to supplement these physician practices.
As expected, we closed InTouch Health, and I can confidently say this is the strongest integration we've had to date. I'm extremely excited to welcome Joe DeVivo, who is now officially the President of the newly combined hospital and health systems business, and the entire InTouch team to the Teladoc Health family. Just last week, we were honored to host InTouch Health's 14th Annual Telehealth Innovation Forum for the first time as a combined company, and for the first time, it was a fully virtual event. The Innovation Forum is the premier telehealth event of the year, attracting clients, healthcare leaders, and visionaries from around the world. This year, over 3,500 registered attendees participated in 55 sessions with more than covering topics ranging from virtual care best practices to clinical workflow models.
The engagement within these sessions made it incredibly clear to me that the coming together of these two companies could not have been better timed, and I could not be more excited about the tremendous opportunities ahead for the combined business. When it comes to the performance of the business, we are extremely pleased. The combined offering is resonating in the marketplace, and our ability to deliver a highly secure, interoperable, and fully integrated platform backed by our large network of physicians is driving record pipeline growth. We have recently signed several significant new large clients including new international deals with health systems in Germany, India, and the U.K., demonstrating the ability deals and outpacing our own expectations for activating our international distribution channels. With that, I will turn the call over to Mala for a review of second quarter financials as well as detailed 2020 guidance.
Thank you, Jason, and good afternoon, everyone. During the second quarter, total revenue increased 85% to $241 million. Global subscription access fee revenue for the quarter of $182 million grew 64% versus the prior year, demonstrating significant momentum. U.S. subscription access fee revenue of $152 million grew 78%, and international subscription dollars grew 17%. Of the dollar versus foreign currencies resulted in a negative FX impact of $1.3 million. Annual revenue growth was 22 basis. Increased to $58.9 million, representing growth of 200 the prior year, in part aided by the surge in volume quarter due to the evolving. Revenue fee access was $19.5 million in the quarter, representing nearly 450% growth versus the prior year, driven in part by rapidly accelerating utilization amongst new populations added in the back half of 2019.
Visit fee revenue comprised 24.4%, up significantly from 14.6% of revenue in the prior year's quarter, as we have experienced considerable increases in utilization. Turning to membership and access, U.S. paid membership increased to 51.5 million members, up 92% versus the second quarter of last year. Of the 8.5 million new paid members added in the quarter, approximately 1.5 million have been onboarded on a temporary basis on behalf of our clients. Individuals with visit fee only access was 21.8 million at the end of the first quarter, million versus the prior year, and 2.6 million sequential. Anticipated visit fee only includes access for approximately 2.5 that we anticipate will roll off by year-end. Total visit volume of approximately 2.8 million visits in the quarter, represented over prior year. Visit volume from paid members in the 125%, which represents an annualized utilization rate of compared to 9% in last.
Excluding the impact populations onboarded over the last 12 months, annualized utilization during the second quarter would have been. PMPM in the quarter was $1.02 compared to a quarter. As we have previously discussed, we expect to see a dampening effect on average PMPM when we onboard large new health plan member populations. Adjusted gross profit increased by $62 million to 151% as compared to the prior year second quarter. Adjusted to exclude amortization of intangibles was 62.3% compared to 68% in the second quarter of last year and 60% in the first quarter. The year-over-year decline in gross margin is attributable to the robust visit growth and increase in visit fee revenue mix in the quarter.
The sequential improvement in gross margin reflects significantly lower investment in physician capacity, despite a 35% sequential increase in visit volume, as the investments we made during the first quarter paid off. Operating expense for the quarter totaled $157 million or 65% of revenue compared to 85% in the second quarter of 2019. Excluding non-cash charges such as depreciation and amortization, stock compensation and one-time acquisition and integration related expenses, quarterly adjusted operating expenses were $124 million or 51% of revenue, compared to 63%. Adjusted EBITDA increased to $26.3 million for the quarter, million in the second quarter of 2019. Adjusted EBITDA margin expanded 600 basis points over the prior year second quarter to 10.9%. EBITDA, including stock compensation and one-time acquisition related costs, was a positive $2.7 million compared to a $12.2 million EBITDA loss in the same period last year.
Net loss in the quarter was $25.7 million compared to a net loss of $29.3 million in the second quarter of 2019. Net loss was $0.34 for the second quarter in the second quarter of last year. Per share includes a $0.10 associated with our May 2020 convertible debt offering, which includes the charge associated with a portion of our previously outstanding debt that was to mature in 2022. We ended the quarter with over $1.3 billion in cash and short-term investments, while our total debt outstanding as of June 30th was $1.3 billion. Now turning to forward guidance. Note that the guidance now includes the results of InTouch Health, which closed on July 1st. For the third quarter of 2020, we expect total revenue of between $275 million-$285 million, representing growth of 100%-107% over the prior year's quarter.
We expect total U.S. paid membership of 50 million-51 million, excluding the approximately 1.5 million temporary members onboarded during the second quarter. We anticipate total visits during the third quarter of between 2.5 million and 2.7 million. We expect third quarter EBITDA to be in the range of -$3 million to +$1 million, adjusted EBITDA of between $27 million and $31 million, and net loss per share to be between $0.35 and $0.30 based on 83.4 million shares outstanding. For the full year 2020, we now expect revenue to be in the range of $980 million-$995 million, as Jason said, up from our prior $800 million-$825 million range, representing 77%-80% growth over the prior year, including approximately 60% growth.
We expect total U.S. paid membership at year-end of over 50 million members, representing at least 36% membership growth as compared to 2019, and Visit fee-only access to be available to approximately 19 million-20 million individuals. We have increased our expectation for visits between 9.8 million and 10.3 million for the year, representing total visit growth of approximately 135%-150% over the prior year. Our visit outlook does volume resulting from a second surge of COVID-19, which many experts are predicting will occur later this year. We expect EBITDA in the range of - $13 million to - $6 million and adjusted EBITDA in the range of $85 million-$92 million, representing growth of approximately 165%-190% over the prior year.
The expected EBITDA improvement reflects the significant growth in revenue in conjunction with our continued focus on operating efficiencies, while still allowing us to continue to make significant investments in growth. We expect to continue to invest in future growth opportunities, including increased adoption of virtual care and in the tremendous opportunity set combined hospital and health system business. Net loss per share is expected to range from a loss of $1.45-$1.36 per share based on 79.6 million weighted shares outstanding. We expect cash flow from operations to grow consistent with adjusted EBITDA growth. Similar to the second quarter results, the full-year net loss per share includes a $0.10 net impact associated with our May 2020 convertible debt offering, which includes a charge associated with the loss on extinguishment of a portion of our previously outstanding debt that was to mature in 2022.
Today, I will also provide you some standalone financial metrics for InTouch to help guide your modeling. Note that after today, we do not expect to provide standalone InTouch financial results. In the third quarter, we intend to provide operating metrics for the newly combined hospital and health systems business. For fiscal year 2019, InTouch Health generated $85 million of revenue, and we expect that to grow over 35%. For the second half of the year, we expect InTouch will generate [$5 million] of revenue, purchase accounting reduction to deferred revenue. We expect InTouch to approach breakeven adjusted EBITDA in the second half of the year and deliver positive adjusted EBITDA early in 2021. We expect InTouch and the broader hospital and health system channel to deliver revenue growth in line with our long 30% organic revenue growth, gross margins in the mid-60s%.
We see significant opportunities for synergies, including cost synergies in the mid-single digits and revenue synergies well in excess of that. With that, I will turn the call back to Jason for closing remarks.
Thanks, Mala. Before we turn to Q&A, I'd like to take a moment to put into context how we think about the significant financial numbers we've shared with you today. Earlier this month, I hosted one of our company's regularly scheduled town hall meetings. These meetings are typical in many ways, with business updates and a discussion of critical issues. In this case, we discussed our work on diversity and our approach to returning to the office someday. Regardless of the topics, we always start with a patient story to ground us in why we do what we do. While I'm not going to do that today, it's clear to all of us here at Teladoc Health that the numbers we've talked about today represent millions of people who were sick, worried, or stressed in the face of an uncertain world.
People who we helped heal represent the thousands of hospitals and physicians who are investing in virtual care to be there for their patients in their time of need today and in the future. The pride that our team feels for these results today is as much about living our mission as achieving outstanding financial performance. We're grateful to share this success with you today. As always, thank you for your continued interest in the Teladoc Health story. With that, we'll open the call for questions. Operator?
Thank you. At this time, I would like to remind everyone, in order to ask a question, please press star, then one on your telephone keypad. We'll pause for just a moment to compile the Q&A roster. Your first question comes from Ryan Daniels with William Blair. Your line is open.
Thanks for taking the questions. Jason, maybe one for you. Clearly, we've seen mainstream on a very rapid basis, and I guess the only really outstanding question is, what's the long-term reimbursement outlook? I'm curious what you guys are doing from a marketing or just an engagement standpoint to ensure that this momentum continues, that it's not near-term in nature and that this really does become mainstream and is kind of a typical form of utilization for consumers as we look forward over the next few years.
Yeah. Thanks, Ryan. I'd say a couple of things. First of all, the momentum that we're seeing is broad-based across the entire business, which is a really strong indicator and gives me tremendous confidence that this not only has become part of the mainstream, but will continue to grow at a very strong clip. We are continuing to use our engagement engine in order to drive first-time users, right? If you saw, or if you heard in the prepared remarks, first-time users were up significantly, new registrations up over 150% year-over-year. As we talked about in our Investor Day at the beginning of March, once we get them in the top of the funnel, then the flywheel takes effect. We're seeing people who used more than one clinical service increase substantially over the course of this quarter relative to prior quarters.
I think all of those things part of consumers access care. Lastly, I would say enabling the providers to deliver virtual care will serve to make virtual care part of how consumers expect to get healthcare, not a novelty, which it may have been just a few years ago.
Your next question comes from Lisa Gill with JPMorgan. Your line is open.
Thanks very much. Jason, congratulations on another outstanding quarter. We think about 2021, and thank you for giving that preliminary outlook, I just want to understand just a couple of different components to this. I appreciate the numbers that you put out there for InTouch. If I were to back out what Mala just talked about, it looks like you're still anticipating that the organic growth rate's gonna be in that 20%-30% range, even though the company is materially bigger than what it was. I'm just curious as to what your anticipation is going forward for utilization trends. I think you talked a little bit about this in your prepared remarks, that even in places where things have started to open back up, you're still seeing strong utilization. Maybe if, one, you could start there and talk a little bit about that.
Two, how does the selling season backfill into that? You talked about a new client coming on in October, how do things look for 01/01/2021?
Okay. You got a lot in there, Lisa. Thanks for the question and your comments. I'll start with visit volumes and utilization. As I mentioned at the bottom of the U-shaped curve, we were seeing visit volumes roughly 40% higher than pre-COVID. That gives us good insight into what to expect in the back half of the year. We're gonna stop short of giving just, but I think, again, we mentioned that we're seeing twice the rate of growth that we were seeing prior to the COVID onset. I think you can sort of triangulate on where we're going relative to visit volumes and utilization. Again, that gives us tremendous confidence in next year. The second thing relative to the selling season is that our bookings are up about 70% year-over-year.
In every single channel that we look at, they're up at least 50% year-over-year for the first half of this year. Two-thirds of our bookings are for multi-product sales, which is up from about 50% last year. We're seeing that trend continue. Our average deal size is up 50% year-over-year on top of what was a 50% increase last year. All of those things give us tremendous confidence as we look into the growth into the future.
Lisa, I'll add a couple of other things as we look into the future. Jason talked about utilization. He talked about multi-product and the robustness of the selling season. The other dynamics that we are seeing is, as we've talked about, we see a tremendous expansion in our member base this year. As you know, the utilization on those will ramp over time. That is a dynamic to keep in mind as we think about 2021. The momentum that we are seeing, and we expect to continue. There are many tailwinds that really go into the view that we have.
It is early, and there are various other macro factors at play that continue to evolve, but we felt that it was important for you all to at least have a preliminary placeholder on how we are thinking about our growth for next year.
Again, if you'd like to ask a question, please press star one. Your next question comes from Stephanie Davis.
Hey, guys. Congrats on a really strong quarter, and Joe, welcome to the team.
Definitely.
Another question on the hospitals. To your differentiation versus some of the tech pure plays like Zoom or Microsoft Teams, as we're seeing more HIPAA compliance.
Yeah. First, let me talk a little bit of the tremendous momentum that we're seeing there. We've seen RFPs actually triple from Q1 to Q2 as hospitals and health systems move to rapidly embrace virtual care in a changing landscape. 80% more client expansions in the quarter. Over 20% increase in new clients. Really tremendous momentum. I think I mentioned in the call the success of our international expansion. We activated that channel much faster than I expected to. I think all of that points to the change that we're seeing in how hospitals are thinking about virtual care and the technology that enables it. It's much more important, and some of them did put in sort of Band-Aids, if you will, stopgap measures in order to meet initial demand for single use cases.
What we're seeing is that hospitals are looking for an enterprise-wide solution that is secure, that is managed, that is medical-grade reliability, and that can both bring the doctor to the bedside as well as into the home. InTouch Health and Teladoc Health together are uniquely positioned to be able to do that, unlike any of the sort of off-the-shelf video platforms that aren't really designed to grade it into the healthcare system. We really see that that is going to continue to be a rapidly growing channel and a competitive advantage for us.
Follow up on that. You've talked about this RFP tripling. Is there any sense of how penetrated the hospital environment is? Is this going to be kind of like a 2020 penetration story and then tapers off in 2021, or is there more runway post this?
There's tremendous runway. Together, we serve 60 of the top 100 hospitals, when you combine the two organizations. We're barely penetrated in terms of the use cases, the number of physicians who are on the platform. With each additional clinical use case, with each additional physician group and specialty that embraces virtual care, that's expansion opportunity for us. You heard me say that we had 50% more client expansions in the quarter than we had previously, but the runway is tremendous in front of us. We're really just scratching the surface in the hospital and health system space.
Yeah, the last thing I would add, Stephanie, is that expansion and the runway is not just inside the four walls of the hospital, right? If you think of what the two of us bring together as Then exponential impact of that.
Maybe last thing I'll add there is, we find that physician groups and large health systems alike find significant value in our provider network because we can bring additional capacity to the health system or the physician practice.
Your next question comes from Sean Wieland with Piper Sandler. Your line is open.
Hi. Thanks. Let me add my congrats to an incredible release here. I just have a few more questions on the InTouch integration and want to get a little bit more detail. Jason, you mentioned last quarter you identified 100 use cases for the combined assets of InTouch and Teladoc. If you can maybe touch on one or two of those that are resonating in the market right now. From a reporting standpoint, I appreciate the disclosure on the numbers for InTouch, but how is it going to be reported within the context of the existing operating metrics you provide, or will there be new operating metrics?
Yeah, Sean, let me address the reporting first, and then I'll turn it over to Jason. We'll consolidate InTouch into our overall reported revenues. What we do expect is that the majority of that revenue will really be an access fee revenue. We do expect to consolidate it all into our revenues.
With respect to the use cases, it was really amazing to go through the Telehealth Innovation Forum and listen to clients talk about their use cases. They ranged from pre-admission consultations to post-discharge follow-ups, ranged from oncology to NICU use cases. Of course, telestroke continues to be a very significant use case. As you might imagine, with people being concerned about going into the hospital, you see everything from orthopedists to cardiologists going virtually into the consumer's home to deliver care and make sure that the patients are getting the care that they need. It's really an incredibly broad spectrum. What's great about the Innovation Forum is you get the sharing of that information and best practices, we frequently see that hospitals and health systems implement some of those use cases and best practices that they learned at the Innovation Forum.
Yeah. Sean, just one quick thing. Just so that we can provide a measure of transparency into how this business is progressing, as we said in our prepared remarks, we will put out some operating metrics starting next quarter.
Your next question comes from Sandy Draper with SunTrust. Your line is open.
Hi, this is Stan on for Sandy. Thanks for taking my questions. Last quarter, I believe you commented that you've kind of evolved your higher capacity on the platform. Just an update on capacity levels, utilization? Any changes there?
Yeah. Thanks, Stan. Our capacity, as you know, we expanded our capacity dramatically, in the second half of March in response to a significant increase in visit volume. That was a time of tremendous innovation that enabled us to onboard thousands of physicians very efficiently, and we benefited from that over the course of this quarter. In spite of significantly higher than expected visit volume, you saw the investments that we made in the first quarter pay off in the second quarter, and that accounts for some of the improvement in our gross margins. As you'll note, we had significantly higher visit volume in the second quarter than the first quarter, and yet our gross margins increased. That's a direct result of all that additional capacity that we added.
Lastly, you'll see or you'll hear, or you heard in our prepared remarks. That is in part due to the tremendously strong responder, where with that incredibly high volume of visits, we're down under 10-minute, usually between five and 10-minute response times. We feel very pleased with that, and we feel like we've made the investments that will pay off into the future.
Your next question comes from Daniel Grosslight. Your line is open.
Hey, guys. Thanks for taking the question. I want to go back, Jason, to that comment, media company. As I look at the landscape here, there's been a lot of reports about some of your peers falling down. Key environment for 2021 and the rest of this year. Do you think you'll see an increase in RFPs from some of the health plans that may have entrenched relationships with other vendors? How do you see that competitive takeaway going as we look to model 2021?
Thanks, Daniel. We do see significant opportunities to penetrate clients who have historically worked with someone else. Maybe they went for a lower cost alternative in the past, and they're not meeting their expectations. We have improved our relationships with our existing clients. The media company that I mentioned, they were an early adopter of telemedicine with another company, and we're very pleased to provide them our entire suite of clinical services. We see that as a continuing trend, both among employers as well as among health plans.
Another trend that we are continuing to see is the strength in our cross-sell/upsell efforts. We've talked in the past about land and expand. The proof positive of that is the strength that we are seeing in our cross-sell/upsell. Again, that is another trend and dynamic that we're seeing as we think about the selling season ahead.
Great. Thanks, guys.
Your next question comes from Charles Rhyee with Cowen. Your line is open.
Yeah. Thanks for taking the questions and congrats on the quarter and the strong outlook. Maybe Mala, I just wanted to follow up to an early question about how we model, and I think you said think of InTouch mostly going into the access fee revenue. Is there a visit component that we should be modeling in, or should we not really touch the visit line, sort of the visit assumptions, to incorporate InTouch to consolidate down into revenues. I guess more broadly to that, as we think about the pricing model, is it really just subscriptions, and is it sold modularly? Maybe if you can just give us a little bit more color into sort of how the pricing model works on the InTouch side. Thanks.
Yeah. In terms of the composition of the revenue, think of it as primarily access revenue. More specifics than that, Charles, but I would say primarily, sorry, access revenue. In terms of revenue, sort of economic model, the way the InTouch business works is that we get paid both on a licensed user basis, as well as on a per care location basis. There are a couple of different ways that we do get paid, in terms of the overall economic model. I'm going to leave it at that. I don't want to get into any more specifics.
Your next question comes from George Hill with Deutsche Bank. Your line is open.
Hey, good evening, guys, thanks for taking the question. Jason, I'm going to try to sneak in two real quick. First is, I'd love to ask about how you think of the evolution of the model of telemedicine, what I would call the provider-anchored model versus the payer-anchored model. I know that you guys sell both, but most of your revenue comes from the payer-anchored model. I'd love any comments you'd be willing to make on step-ups in utilization by disease state. I'm particularly interested in behavioral. Thank you.
Thanks, George. Look, I think telemedicine is here to stay, and it's here to stay all across the spectrum of how healthcare is delivered. As you know, it's always been our strategy to be at every front door of the healthcare system. Virtual care, we're very happy to do it for our providers by providing technology for them, and you see all the numbers. I just saw new numbers come out from HHS about Medicare usage of telemedicine, and it seems to be persistent, and that's not surprising to me. Those are similar to the trends we're seeing among our provider clients. 50% of consumers don't have a primary care physician, and so ours, through the payer, used to be a critical ensure that consumers are getting the care that they need on their terms.
We deliver it in a way that is incredibly high quality and cost efficient. I think all of those things very much embrace our strategy at going after every part of the healthcare system. Then you asked about utilization, and so I'll give a few pieces of insight there, because I think you asked about disease states, which is really important. Mental health technology have increased substantially, where even faster than our general medical visit on just an absolutely torrid pace. Mental health, 40% of people say that they wouldn't have sought care, if it weren't for having access to our services. Which is just a tremendous need in terms of people who don't get the care that they need, either because of stigma or access or cost, or something else.
We're also seeing a significant increase in usage for non-infectious diseases, and that's actually grown faster than infection. Today, about 60% of our general medical visits are for non-infectious diseases, whereas it was only about 40%. I think that really speaks to the. For the first time, we're seeing hypertension in addition to anxiety, climb into our top 10 visits list, or top 10 diagnoses list, which is very interesting and I think portends a very bright future in terms of the impact that we can have on the overall healthcare system.
Your next question comes from Matthew Gillmor with Baird. Your line is open.
Hey, thanks for the question. Jason, I appreciate the comments on causing a revolution if the system went back on telehealth coverage and reimbursement. I was curious what you are hearing from employers and payers with respect to co-pay levels and how long that stays at $0 or will that be more of a permanent change as well?
Yeah. We're seeing positive signals about that continuing. We've seen some large employers and health plans extend the zero co-pay through this period of time, and into the future, some even into next year already. We're positive on that. I think people have realized the benefit that virtual care can have into the future, regardless of what the COVID curve looks like. With respect to reimbursement at the federal level, you probably saw, Matt, that the Senate COVID relief package that was proposed earlier this week, proposes to extend the waivers or the Medicare waivers through the end of 2021. I think when you combine that with Secretary Azar's comments and the fact that there are several bills in Congress to remove the originating site and rural restrictions, I think it's really here to stay in terms of Medicare reimbursement.
Your next question comes from Sean Dodge with RBC Capital Markets. Your line is open.
Thanks. Good afternoon. Maybe on virtual primary care. Jason, you spent a lot of time talking about that at the Investor Day. Can you give us an update on the progress there? I guess, how far away do you think you are from having all of the necessary pieces for that in place and standing up commercially, and what are those first iterations of it, I guess, going to look like?
As we promised, we launched our VPC pilot, Virtual Primary Care pilot, in Q2. The initial results have been really strong and incredibly interesting. A very broad array of clinical diagnoses, in fact, almost 70 clinical diagnoses within the pilot population, ranging from chronic to acute to complex, ranging from many preventative screenings have been recommended and then actually the screening that they need, whereas they had no plan to do that before their visit. All of that is very positive. We're also seeing a really interesting and broad mix of age groups accessing that care and really engaging well with the overall longitudinal nature of that program. We have active processes going on in the pipeline with several large payers and employers. I would expect that we will be commercially live the first half of next year since we're still in those discussions.
The payment model ranging from discussions about risk-sharing arrangements, primary care capitation, to fee for service, to traditional PMPM plus visit fees. I think you're going to see us come out with a number of different models. I think the most important thing is putting all the pieces in place to deliver on the promise of virtual primary care.
Your next question comes from Jailendra Singh with Credit Suisse. Your line is open.
Thanks. I was wondering if you guys can talk about your M&A focus and opportunities you're seeing with more than $1.3 billion cash in balance sheet. You guys have pretty good financial flexibility. Just wondering if you guys can highlight some of the areas you might be interested in.
Sure, Jailendra. I think our focus continues to be on expanding the markets that we serve and the clinical breadth of our product portfolio. With the vast population that we now have that has access to the platform, we're in a unique position to be able to put more products through that platform, make our clinical impact broader and deeper, and to do it in more markets. We continue to look at geographic expansion internationally. We've had some great success internationally organically this year, with significant wins among the largest financial services company in the Nordic region, which gives us a foothold there, a significant win in Brazil that really expands our footprint there with one of the largest health insurers in the Brazilian market. We continue to look at geographic expansion, both organically and through M&A.
We will continue to look to expand our clinical scope and the impact that we can have across the entire spectrum of clinical use cases and clinical needs.
Yeah. The thing I would also add, Jailendra, is, and we have said this before, when we look at markets outside the U.S., we will be surgical, we will be targeted. We will look for how ripe and favorable the conditions are in those markets for telehealth from a regulatory perspective, et cetera. Exactly like Jason said, it's about adding more products and services as well as expanding our footprint in a disciplined way outside the U.S.
Our last question comes from David Larsen with Verity Research. Your line is open. David Larsen, your line is open.
Sorry about that, was on mute. Can you talk a little bit about your relationship with UnitedHealth Group? I imagine it takes a lot of investment and time to build a telehealth capability. Thanks.
Sure. I appreciate the question, David. We have a great relationship with United. We continue to expand the products and services with United as well as the businesses within United that we serve. As you know, they're a very large organization with multiple businesses, and we continue to expand the scope of our offerings to facilitate virtual care for their members as well as for their own provider organizations. I would characterize it as a very strong relationship.
Dial tone of the call back to the presenters for any closing remarks.
Well, thanks everybody for tuning in. We're very pleased with the results in the quarter and our outlook for the rest of this year and next year. We look forward to continuing to keep you up to date on our progress. Thank you.
This concludes today's conference call. You may now disconnect.